Mission Bio Tapestri Genome Integrity CNV Solution
Mission Bio has launched the Tapestri Genome Integrity CNV Solution, a high-throughput single-cell platform to help cell and gene therapy developers and oncology researchers measure genome-wide copy number variants. The assay features automated reporting and multiplexing capabilities, and enables cell and gene therapy developers to uncover potentially adverse chromosomal events while simultaneously measuring genome editing outcomes. For oncology researchers, the solution enables the assessment of cell-to-cell aneuploidy and CNV events across the genome with the potential to co-measure SNVs and focal CNVs, Mission Bio said.
Takara Bio Europe Shasta Single-Cell System
Takara Bio Europe, a wholly owned subsidiary of Takara Bio, has launched the Shasta Single-Cell Next-Generation Sequencing System. According to Takara, the Shasta platform and Shasta Whole-Genome Amplification Kit increase the throughput for single-cell analysis by processing up to 1,500 cells per run and can detect single-cell level CNV events via shallow sequencing. Meanwhile, the Shasta Total RNA-Seq Kit can offer full gene body coverage of up to 100,000 cells per run, and is capable of detecting RNA biotypes, such as non-polyadenylated lncRNAs.
Biotype Modaplex FGFR3 Mutation and Gene Fusion Kits
Biotype has launched two additions to its Modaplex PCR-based assay portfolio, the Modaplex FGFR3 Mutation Kit and the Modaplex FGFR Gene Fusion Kit, both for research use only.
The company said the assays are designed to detect actionable FGFR alterations in urothelial cancer samples in under five hours. The Modaplex platform enables advanced multiplexing and has high concordance to standard PCR and next-generation sequencing assays, according to Biotype. Tests use an integrated, one-step reverse transcriptase-PCR workflow with automated data analysis.
The FGFR3 Mutation Kit targets 13 actionable mutations in RNA extracted from FFPE tissue blocks. The Gene Fusion Kit allows for parallel detection of 12 clinically relevant gene fusions of the FGFR2 and FGFR3 genes, including seven variants of FGFR3::TACC3. Both assays can run in parallel under the same protocol.
Standard BioTools: SomaScan 11K Assay
Standard BioTools has launched a new version of its SomaScan 11K assay that can make 110,000 total protein measurements in a range of sample types including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates, and cell lysates.
Genialis KrasID
Genialis has launched KrasID, a biomarker algorithm that can predict patient response to KRAS inhibitors across tissue histology and mutation type. It uses machine learning to model biological processes from the gene expression of patient-derived tumors and has been validated on data from non-small cell lung cancer patients as well as from preclinical and patient-derived xenograft samples for colorectal and pancreatic cancer.
LGC Clinical Diagnostics Seraseq ctDNA Mutation Mix v4 Reference Materials
LGC Clinical Diagnostics has launched ctDNA Mutation Mix v4 reference materials. The new version includes 93 variants in 71 genes, among them SNPs, indels, translocations, and CNVs, and is manufactured with a new fragmentation process that delivers lower background noise than previous versions. The reference materials are available at four variant allele frequencies: 0 percent (wild type), 0.1 percent, 0.5 percent, and 5 percent.
CleanNA CE-IVD-Compliant CleanNGS Dx
CleanNA has launched the CE-IVD-compliant CleanNGS Dx, a magnetic bead-based sample prep reagent suitable for next-generation sequencing applications within diagnostic workflows. According to CleanNA, CleanNGS Dx can be used for NGS library cleanup and double-sided size selection in clinical diagnostic settings.
Indian Cancer Genome Atlas Multiomics Data Portal
The Indian Cancer Genome Atlas (ICGA) has launched a cancer multiomics data portal. It provides open access for researchers to clinical and molecular data from Indian cancer patients. Based on the cBioPortal platform, it is the first such portal in India, according to ICGA, and includes DNA, RNA, and protein profiles. The platform currently contains data from 50 breast cancer patients, with plans to expand this number to more than 500 patients over the coming year.
MRC Holland SALSA DigitalMLPA Probemix D001 Hereditary Cancer Panel 1
MRC Holland has launched an update to its SALSA DigitalMLPA Probemix D001 Hereditary Cancer Panel 1. The original assay detected copy number variants in 28 genes and five variants associated with hereditary cancer risk. The updated version has new probes and modifications to existing probes to improve the assay's performance, including probes targeting an exon 2-6 inversion in the MSH2 gene, which is associated with Lynch syndrome. The assay has a turnaround time of 48 to 72 hours and requires at least 20 ng of DNA input per reaction.
For more recently launched products and services, please visit the New Products page on our website.